Robert S. Svatek, M.D., M.S.C.I.

Professor and Interim Chair
Department of Urology

Email: Svatek@uthscsa.edu
Academic Telephone: 210-567-5676
Clinical Telephone: 210-450-9600
Academic Fax: 210-567-6868
Clinical Fax: 210-450-9657
Clinical Profile

Dr. Robert S. Svatek completed Urology residency at the University of Texas Southwestern Medical Center at Dallas from July 2002 June 2007. Dr. Svatek continued his Clinical Fellowship and Research in Urologic Oncology at University of Texas MD Anderson Cancer Center from July 2007 to June 2010 at the same time earned his Master of Science (MS) in Clinical Research Investigation at the University of Texas Health Science Center at Houston, Center for Clinical Research and Evidence-Based Medicine. Dr. Svatek joined UT Health San Antonio in 2010.

Education

MSCI, UT Health San Antonio (2009)
M.D., University of Texas Medical Branch Galveston (2002)

Postgraduate Training

University of Texas MD Anderson Cancer Center, Fellowship, Urologic Oncology (2010)
University of Texas Southwestern Medical Center, Residency, Urology (2007)
University of Texas Southwestern Medical Center, Internship, General Surgery (2003)

Clinical

Dr. Svatek’s expertise is in the evaluation and management of urologic cancers, with a primary focus on patients with bladder cancer. He performs both robotic and open surgery for bladder cancer. He utilizes a comprehensive care plan for patients with bladder cancer that sometimes requires coordination with medical oncologists, radiation oncologists, or both. Dr. Svatek performs surgery at the UT Medicine Ambulatory Surgery Center, University Hospital, Christus Santa Rosa Northwest Hospital, and the Audie L. Murphy Memorial Veterans Hospital. Dr. Svatek sees patients in clinic at the UT Medicine Medical Arts and Research Center.

Research

The major area of interest is in identifying and testing novel therapies for patients with bladder cancer. In addition, he is interested in improving the quality of surgical care for patients undergoing major surgery for invasive bladder cancer.

List of Publications

Svatek RS, Ji N, de Leon E, Mukherjee N, Kabra A, Hurez V, Nicolas M, Michalek JE, Javors M, Sharp ZD, Livi CB, Shu Z, Henkes D, and Curiel TJ. Rapamycin prevents surgery-induced immune dysfunction in patients with bladder cancer. Cancer Immunol Res. 2018 Dec 18. (PMID: 30563829)

Svatek RS, Zhao XR, Morales EE, Jha MK, Tseng TY, Hugen CM, Hurez V, Hernandez J, and Curiel TJ. Sequential Intravesical Mitomycin plus Bacillus Calmette-Guérin for Non-Muscle-Invasive Urothelial Bladder Carcinoma: Translational and Phase I Clinical Trial. Clin Cancer Res. 2015 Jan 15;21(2):303-11. (PMID: 25424854)

Mukherjee N, Ji N, Hurez V, Curiel TJ, Montgomery M, Braun A, Nicolas M, Aguilera M, Kaushik D, Ruan J, Liu Q, Kendrick K, and Svatek RS.  Intratumoral CD56bright natural killer cells are associated with improved survival in bladder cancer. Oncotarget. 2018 Nov. (PMID: 30559932)

Svatek RS, Tangen C, Delacroix S, Lowrance W, Lerner SP.  Background and Update for S1602 “A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-naïve High-grade Non-muscle-invasive Bladder Cancer.  Eur Urol Focus. 2018 Jul;4(4):522-524. (PMID: 30197040)

Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP Jr, Mack PC, Svatek RS, Evans CP, Hafez KS, Culkin DJ, Brand TC, Karsh LI, Holzbeierlein JM, Wilson SS, Wu G, Plets M, Vogelzang NJ, Thompson IM Jr.  Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.  JAMA. 2018 May 8;319(18):1880-1888. PMID: 29801011

Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL 3rd, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN.  Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol. 2017 Oct 20;35(30):3410-3416. (PMID: 28834453)

Svatek RS, Hermann MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI, Shariat SF. Soluble Fas–a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer, 2006 Apr 15;106(8):1701-7. (PMID: 16541433)
Svatek RS, Shah JB, Xing J, Chang D, Lin J, McConkey DJ, Wu X, Dinney CP. A multiplexed, particle- based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer. Cancer. 2010 Oct 1; 116(19):4513-9. (PMID 20572047)

Svatek RS, Shariat SF, Lasky RE, Skinner EC, Novara G, Lerner SP, Fradet Y, Bastian PJ, Kassouf W, Karakiewicz PI, Fritsche HM, Müller SC, Izawa JI, Ficarra V, Sagalowsky AI, Schoenberg MP, Siefker-Radtke AO, Millikan RE, and Dinney CP. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res. 2010 Sep 1;16(17):4461-7. (PMID: 20651056)

Rink M, Shariat SF, Xylinas E, Fitzgerald JP, Hansen J, Green DA, Kamat AM, Novara G, Daneshmand S, Fradet Y, Tagawa ST, Bastian PJ, Kassouf W, Trinh QD, Karakiewicz PI, Fritsche HM, Tilki D, Chun FK, Volkmer BG, Babjuk M, Merseburger AS, Scherr DS, Lotan Y, and Svatek RS. Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy? World J Urol. 2012 Dec;30(6):807-14. (PMID: 22832587)